Lineage Cell Therapeutics Inc. has announced a change in its independent registered public accounting firm following the merger of its current auditor, Moss Adams LLP, with Baker Tilly US, LLP. Effective June 3, 2025, Moss Adams resigned as the company's auditor, and the Audit Committee of Lineage Cell Therapeutics' Board of Directors has appointed Baker Tilly as the new independent registered public accounting firm for the fiscal year ending December 31, 2025. This transition comes after Moss Adams had been the appointed auditor since June 2024. The company confirmed that there were no disagreements or reportable events that required disclosure during this transition period. A formal letter from Moss Adams confirming their agreement with the company's statements has been filed with the U.S. Securities and Exchange Commission.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。